TCGA-F7-A61V-01A-11R-A28V-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.500
- MYC_TARGETS_V2+0.490
- MYC_TARGETS_V1+0.460
- MYOGENESIS+0.350
- E2F_TARGETS+0.340
- DNA_REPAIR+0.320
- ESTROGEN_RESPONSE_LATE+0.270
- G2M_CHECKPOINT+0.260
- FATTY_ACID_METABOLISM+0.250
- P53_PATHWAY+0.160
Top 10 suppressed
- ANGIOGENESIS-0.520
- INTERFERON_ALPHA_RESPONSE-0.510
- INTERFERON_GAMMA_RESPONSE-0.500
- INFLAMMATORY_RESPONSE-0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- IL6_JAK_STAT3_SIGNALING-0.430
- COMPLEMENT-0.420
- TNFA_SIGNALING_VIA_NFKB-0.400
- NOTCH_SIGNALING-0.370
- ALLOGRAFT_REJECTION-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-MZ-A6I9-01A-11R-A31N-07 | — | — | 0.874 |
| 2 | TCGA-CQ-6225-01A-11R-1915-07 | — | — | 0.869 |
| 3 | TCGA-39-5037-01A-01R-1443-07 | — | cohortSQ2 | 0.866 |
| 4 | SRR4195654 | — | — | 0.863 |
| 5 | TCGA-B6-A0RM-01A-11R-A084-07 | — | B | 0.859 |
| 6 | SRR12475110 | — | — | 0.856 |
| 7 | TCGA-BH-A0HU-01A-11R-A034-07 | — | B | 0.855 |
| 8 | TCGA-AO-A0J7-01A-11R-A034-07 | — | B | 0.854 |
| 9 | 63bab58e-1dfd-43df-8188-4b8d766913f3 | — | — | 0.853 |
| 10 | TCGA-33-4532-01A-01R-1201-07 | — | cohortSQ2 | 0.853 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.490 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| MYOGENESIS | 0.350 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.340 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.320 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.270 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.120 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.060 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.030 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.010 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.010 | Idelalisib | — uncovered |